Supernus Pharmaceuticals (SUPN) EBT (2016 - 2025)
Historic EBT for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$58.0 million.
- Supernus Pharmaceuticals' EBT fell 22895.0% to -$58.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.7 million, marking a year-over-year decrease of 12860.73%. This contributed to the annual value of $97.9 million for FY2024, which is 343448.9% up from last year.
- Per Supernus Pharmaceuticals' latest filing, its EBT stood at -$58.0 million for Q3 2025, which was down 22895.0% from $16.7 million recorded in Q2 2025.
- Supernus Pharmaceuticals' EBT's 5-year high stood at $44.9 million during Q3 2024, with a 5-year trough of -$58.0 million in Q3 2025.
- Its 5-year average for EBT is $9.9 million, with a median of $10.9 million in 2021.
- Per our database at Business Quant, Supernus Pharmaceuticals' EBT skyrocketed by 256484.85% in 2024 and then tumbled by 249958.85% in 2025.
- Quarter analysis of 5 years shows Supernus Pharmaceuticals' EBT stood at $2.1 million in 2021, then surged by 1613.31% to $35.1 million in 2022, then plummeted by 97.18% to $990000.0 in 2023, then soared by 2564.85% to $26.4 million in 2024, then crashed by 319.67% to -$58.0 million in 2025.
- Its EBT stands at -$58.0 million for Q3 2025, versus $16.7 million for Q2 2025 and -$5.8 million for Q1 2025.